Want to see TSE:APLI full AI Analyst Report?
APLI Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)72.91K
Market Cap
C$1.99M
Enterprise ValueC$14.88
Total Cash (Recent Filing)C$40.00K
Total Debt (Recent Filing)C$12.94M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding132,366,120
10 Day Avg. Volume40,186
30 Day Avg. Volume72,908
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.11
Price to Sales (P/S)7.60
P/FCF Ratio-1.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistently near-100% gross margins indicate the company’s product economics are structurally favorable once revenues scale. For a clinical-stage biopharma this implies high incremental profitability on sales or licensing, improving long-term margin sustainability and attractiveness to partners.
Focused Infectious-disease StrategyA concentrated strategy on bacterial and viral infections targets a structurally important therapeutic area with steady demand and public-health prioritization. Focus plus a partnering/licensing approach reduces commercialization burden and increases realistic exit or revenue pathways long term.
Improving Cash-burn TrajectoryAn observable improvement in cash burn and a single year of positive operating cash flow show management can materially reduce outflows. While not yet consistent, this trend enhances runway prospects, lowers near-term financing frequency, and makes partnership or licensing deals easier to structure.
Bears Say
Negative Equity And Rising DebtSustained negative equity and materially higher debt reflect accumulated losses and a weakened capital base, limiting financial flexibility. Higher leverage increases refinancing and interest risk, raising the probability of dilutive financing or constrained strategic choices over the medium term.
Chronic Operating Losses; 2026 DeteriorationPersistent net losses and a material worsening of operating results in 2026 indicate the company has not yet achieved earnings power. Continued operating deficits increase reliance on external funding and raise execution risk for clinical programs and commercialization plans over the coming months.
Low, Volatile Revenue BaseLow and inconsistent revenue undermines the company’s ability to self-fund development and scale operations. Revenue volatility complicates planning, reduces bargaining power with partners, and makes cash flow forecasts unreliable, increasing the likelihood of frequent external financing.
Appili Therapeutics Inc Class A News
APLI FAQ
What was Appili Therapeutics Inc Class A’s price range in the past 12 months?
Appili Therapeutics Inc Class A lowest stock price was C$0.01 and its highest was C$0.04 in the past 12 months.
What is Appili Therapeutics Inc Class A’s market cap?
Appili Therapeutics Inc Class A’s market cap is C$1.99M.
When is Appili Therapeutics Inc Class A’s upcoming earnings report date?
Appili Therapeutics Inc Class A’s upcoming earnings report date is Aug 07, 2026 which is in 2 days.
How were Appili Therapeutics Inc Class A’s earnings last quarter?
Appili Therapeutics Inc Class A released its earnings results on Jun 27, 2026. The company reported -C$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Appili Therapeutics Inc Class A overvalued?
According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued.
Does Appili Therapeutics Inc Class A pay dividends?
Appili Therapeutics Inc Class A does not currently pay dividends.
What is Appili Therapeutics Inc Class A’s EPS estimate?
Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Appili Therapeutics Inc Class A have?
Appili Therapeutics Inc Class A has 132,366,120 shares outstanding.
What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?
Appili Therapeutics Inc Class A reported an EPS of -C$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?
Currently, no hedge funds are holding shares in TSE:APLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Appili Therapeutics Inc Class A
Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pipeline includes Favipiravir, utilized for pandemic influenza and COVID-19, and the clinical-stage antifungal ATI-2307, which targets cryptococcal meningitis and invasive candidiasis. Other programs feature ATI-1503, a new class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral metronidazole suspension; ATI-1801, a novel topical formulation of paromomycin for treating cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. Additionally, Appili maintains a strategic collaboration with AiPharma Global Holdings LLC for the ongoing development of Avigan/Reeqonus (favipiravir).